Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Daniel Och, Oz Management Disclose Massive Increase In Holding Of Rockwood Holdings, Inc. (ROC)

Is it a good time to buy Rockwood Holdings, Inc. (NYSE:ROC) shares? Daniel S. Och seems to think so, as he has made a massive addition to his investment in the company. According to a recent filing with the Securities and Exchange Commission, Och has taken Oz Management’s holding from 100 to 4.31 million shares, which gives them control over 5.95% of the total number of shares outstanding.

Och-Ziff Capital Management

Jeffrey Gates is also optimistic about the prospects of Rockwood Holdings, Inc. (NYSE:ROC) and has slightly increased his fund’s holding during the first quarter. Gates Capital Management reported ownership of 2.52 million shares in its latest 13F filing. William B. Gray is also a fan, having boosted his fund’s stake in the company by 7% during the same period of time. Gray’s fund, Orbis Investment Management, reportedly holds 3.95 million shares. Jean-Marie Eveillard, on the other hand, has chosen to limit his fund’s exposure to Rockwood Holdings, Inc. (NYSE:ROC). His fund, First Eagle Investment Management, reportedly holds 3.65 million shares, down 28% during the Q1 of 2014.

Disclosure: none.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!